Naporafenib not checked
Erasca · Novartis Pharmaceuticals · ERAS-254 · LXH254
FollowEvery change as it happens, and a Monday email
Trials
4 active
7 in total · 4 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-rafenib: Raf kinase inhibitors WHO name stem
- How it’s given
- “Naporafenib (ERAS-254) 200 mg twice daily (BID) of an experimental Pan-Raf inhibitor”In the company’s words, NCT05907304 on ClinicalTrials.gov
- Tested for
- Advanced or Metastatic NRAS-mutant Melanoma, Melanoma, Advanced or Metastatic Solid Tumors, EGFR-mutant Non-small Cell Lung Cancer
- Main trialPhase 3
- “Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).”In the company’s words, NCT06346067 on ClinicalTrials.gov
- Other names
- ERAS-254 · LXH254
Other drugs for Advanced or Metastatic NRAS-mutant Melanoma
- PembrolizumabMerck & Co. · Phase 3
- CemiplimabRegeneron · Phase 3
- DarovasertibIDEAYA Biosciences · Phase 3
- FianlimabRegeneron · Phase 3
- BCD-217Biocad · Phase 3
- ISCIB1+Scancell Ltd · Phase 3
Coming up3
- 2 Feb 2027Phase 2 trial completes · ClinicalTrials.gov
- 12 Jul 2027Phase 1 trial completes · ClinicalTrials.gov
- Apr 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Apr 2028 | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | |
| Phase 2Active, not recruiting | 2 Feb 2027 | Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | |
| Phase 1Active, not recruiting | 1 Jul 2025 | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations | |
| Phase 1Active, not recruiting | 12 Jul 2027 | Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | |
| Phase 1Terminated | 18 Feb 2022 | Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations | |
| Phase 1Terminated | 24 Apr 2024 | A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | |
| Phase 1Terminated | 25 Sep 2024 | A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026